retatrutide triple agonist glp-1 gip glucagon From Obesity to Metabolic Health: Why Is a Game-Changer retatrutide triple agonist glp-1 gip

Diabetes also increases the morbidity and mortality of these patients, by contributing to higher rates of infections, cardiovascular events, and malignancy

Adherence 14 , 23372345 (2020)

Addressing Cost Barriers A key motivation behind the GLP-1 Bridge is the high cost of these medications

We dont have nonsurgical therapies that directly target cardiovascular risk-associated overweight or obesity and the related metabolic abnormalities

By alleviating chronic systemic inflammation, GLP-1RAs may help prevent the progression of HF and adverse cardiovascular events

Qian P, Tian H, Wang Y, Lu W, Li Y, Ma T, Gao X, Yao W